PT  - JOURNAL ARTICLE
AU  - Chen, Fan-En
AU  - Lee, Pei-Wei
AU  - Park, Joon Soo
AU  - Trick, Alexander Y.
AU  - Chen, Liben
AU  - Shah, Kushagra
AU  - Hsieh, Kuangwen
AU  - Wang, Tza-Huei
TI  - Point-of-Care CRISPR-Cas-Assisted SARS-CoV-2 Detection in an Automated and Mobile Droplet Magnetofluidic Device
AID  - 10.1101/2021.01.27.21250564
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.01.27.21250564
4099  - http://medrxiv.org/content/early/2021/01/31/2021.01.27.21250564.short
4100  - http://medrxiv.org/content/early/2021/01/31/2021.01.27.21250564.full
AB  - In the fight against COVID-19, there remains unmet needs in developing point-of-care (POC) diagnostic testing tools that can rapidly and sensitively detect the causative SARS-CoV-2 virus to control disease transmission and improve patient management. Although recent CRISPR-Cas-assisted SARS-CoV-2 detection assays (such as DETECTR and SHERLOCK) are viewed as transformative solutions for POC diagnostic testing, their lack of simple sample processing and full integration within an automated and portable device hamper their potential for POC use. We report herein POC-CRISPR – a new single-step CRISPR-Cas-assisted assay that is coupled to droplet magnetofluidics (DM) – that leverages simple magnetic concentration and transport of nucleic acid-binding magnetic beads to accomplish sample preparation and assay automation. By further adapting the assay into a fully integrated thermoplastic cartridge within a palm-sized mobile device, POC-CRISPR was able to detect 1 genome equivalent (GE)/µL SARS-CoV-2 RNA from a sample volume of 100 µL in 30 min. Moreover, when evaluated with unprocessed clinical nasopharyngeal (NP) swab eluates, POC-CRISPR identified SARS-CoV-2 positive samples in as short as 20 min and achieved full concordance with standard RT-qPCR.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors are grateful for the financial support from the National Institutes of Health (R01AI138978 and R61AI15462). KH is grateful for the financial support from the Sherrilyn and Ken Fisher Center for Environmental Infectious Diseases at Johns Hopkins University (FCDP‐010ZHA2020).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Johns Hopkins Medicine Institutional Review BoardsAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the corresponding author, KH and THW, upon reasonable request.